ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

9:00AM-11:00AM: Abstract Number: 0366

Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0095

Systematic Evaluation of Nine Monogenic Autoinflammatory Diseases Reveals Common and Disease-Specific Correlations with Allergy-Associated Features

Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

9:00AM-11:00AM: Abstract Number: 0245

Systemic Lupus Erythematosus Phenotype Risk Score Identifies Undiagnosed Cases in a Large Electronic Health Record

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

9:00AM-11:00AM: Abstract Number: 0269

Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

9:00AM-11:00AM: Abstract Number: 0426

T-Cell Receptor (TCR) Sequencing Reveals Decreased Diversity and Clonotypic Expansion of T-cells in Relapsing Polychondritis (RP)

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0319

Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Area and Severity Index 100 and Beyond: Insights from Open-Label, Assessor-Blinded Study at Week 24

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0288

Targeted Sequencing Revealed Novel Candidate Genetic Contributions to Lupus Nephritis in a Cohort of Swedish Patients with Systemic Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0103

The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative

Osteoporosis & Metabolic Bone Disease Poster

9:00AM-11:00AM: Abstract Number: 0096

The Bicipital Stress Test: A Maneuver to More Accurately Diagnose Bicipital Tendinitis and Its Referred Pain Patterns

Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

9:00AM-11:00AM: Abstract Number: 0197

The Clinical and Laboratory Features of Seronegative Rheumatoid Arthritis with and Without Malignancy

RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity

9:00AM-11:00AM: Abstract Number: 0266

The Correlation Between Pregnancy, Disease Activity and Adverse Pregnancy Outcomesin Patients with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

9:00AM-11:00AM: Abstract Number: 0065

The Energy-dependent Hierarchy of Immune Functions in Human Monocytes

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0350

The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0134

The Impact of Exercise on Sleep in People with Rheumatoid Arthritis: A Pilot Randomised Controlled Trial

Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

9:00AM-11:00AM: Abstract Number: 0325

The Impact of PsA Disease Control Status on Patient Treatment Satisfaction: Real-world Survey in US and Europe

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].